Key Highlights

  • Acadia Pharmaceuticals shares are trading at $23.15 in pre-market activity, down 8.97% from Wednesday's close of $25.43.
  • The company's drug remlifanserin narrowly missed the primary endpoint in the Phase 2 portion of the RADIANT trial for Alzheimer's disease psychosis, with a standardized effect size of 0.26 and a p-value of 0.0603.
  • The drug did achieve nominal statistical significance on a key secondary endpoint, with a standardized effect size of 0.37 and a p-value of 0.0077.
  • Acadia plans to continue enrolling its ongoing Phase 3 studies while removing the lower 30 mg dosage arm from the program.

Primary Endpoint Narrowly Missed, but Secondary Signal Holds

Acadia Pharmaceuticals (NASDAQ:ACAD) shares are falling pre-market after the company reported topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer's disease psychosis. The 60 mg once-daily dose narrowly missed the primary endpoint of change in hallucination and delusion symptoms, posting a standardized effect size of 0.26 against a significance threshold, with a p-value of 0.0603. The drug did achieve nominal statistical significance on the key secondary endpoint measuring overall symptom severity, with a stronger effect size of 0.37 and a p-value of 0.0077, and the treatment effect widened over the six-week study period on both measures.

Favorable Safety Profile Supports Continued Development

Across both doses studied, remlifanserin showed a favorable safety profile, with rates of adverse events and discontinuations similar to placebo, no signal of QT prolongation, and no evidence of negative impact on motor symptoms or cognition. Based on the totality of the data, Acadia plans to continue enrolling its two ongoing Phase 3 studies while amending the program to remove the lower 30 mg dosage arm, which showed minimal improvement over placebo, focusing future development on the 60 mg dose that showed the stronger treatment signal.

A Large Unmet Need With No Approved Treatment Option

Acadia Pharmaceuticals is a San Diego-based commercial-stage biopharmaceutical company focused on central nervous system disorders and rare diseases, with an existing portfolio including the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. There is currently no FDA-approved therapy for Alzheimer's disease psychosis, a condition affecting roughly 30% of the more than 7 million Americans living with Alzheimer's disease, and the company plans to present detailed results from the RADIANT study at a major Alzheimer's disease conference in November.